Evaluation of the Antiproliferative Effects of a Newly Synthesized Benzimidazole Compound on Prostate Cancer Cells

Abstract

Benzimidazole is a versatile scaffold with considerable anticancer potential due to its structural resemblance to nucleosides and its ability to function as both a hydrogen bond donor and acceptor, enabling interactions with multiple molecular targets involved in cancer progression. Numerous benzimidazole-based anticancer agents have been reported in the literature, highlighting the importance of this core structure. In this study, a novel benzimidazole derivative, SA-17, was synthesized and its anticancer activity was evaluated in the human prostate cancer cell line PC3. Cytotoxic effects were assessed in vitro using the MTT assay. Cellular proliferation was analyzed in PC3 cells following 72 hours of exposure to varying concentrations of SA-17 and the reference drug nilotinib. The results demonstrated significant differences in cell viability depending on the concentration applied. High concentrations of SA-17 (150 µg/mL and above) exhibited strong cytotoxic and antiproliferative effects against PC3 cells after 72 hours of incubation. However, nilotinib showed greater efficacy than SA-17 in reducing PC3 cell viability. Overall, the findings suggest that structural modifications of benzimidazole derivatives hold substantial potential for the development of effective anticancer agents.

Keywords

• Cancer
• Cytotoxic activity
• PC3 cells
• Benzimidazole

Supporting Institution

Süleyman Demirel University

Project Number

TSG-2024-9516

Thanks

The authors gratefully acknowledge the financial support from the Suleyman Demirel University Research Fund, specifically under the grant numbered TSG-2024-9516

Yeni Sentezlenen Bir Benzimidazol Bileşiğinin Prostat Kanser Hücreleri Üzerindeki Antiproliferatif Etkilerinin Değerlendirilmesi

Abstract

Benzimidazol, nükleositlere yapısal benzerliği ve hem hidrojen bağı vericisi hem de alıcısı olarak işlev görme yeteneği sayesinde kanser ilerlemesinde rol oynayan birden fazla moleküler hedefle etkileşime girebilmesi nedeniyle önemli bir antikanser potansiyeline sahip çok yönlü bir iskelettir. Literatürde çok sayıda benzimidazol bazlı antikanser ajanı bildirilmiş olup, bu temel yapının önemini vurgulamaktadır. Bu çalışmada, yeni bir benzimidazol türevi olan SA-17 sentezlendi ve antikanser aktivitesi insan prostat kanseri hücre hattı PC3'te değerlendirildi. Sitotoksik etkiler, MTT testi kullanılarak in vitro olarak değerlendirildi. Hücre çoğalması, PC3 hücrelerinde SA-17'nin ve referans ilaç nilotinibin farklı konsantrasyonlarına 72 saatlik maruz kalmanın ardından analiz edildi. Sonuçlar, uygulanan konsantrasyona bağlı olarak hücre canlılığında önemli farklılıklar olduğunu gösterdi. Yüksek konsantrasyonlardaki SA-17 (150 µg/mL ve üzeri), 72 saatlik inkübasyondan sonra PC3 hücrelerine karşı güçlü sitotoksik ve antiproliferatif etkiler sergiledi. Ancak nilotinib, PC3 hücre canlılığını azaltmada SA-17'den daha yüksek etkinlik göstermiştir. Genel olarak, bulgular benzimidazol türevlerinin yapısal modifikasyonlarının etkili antikanser ajanlarının geliştirilmesi için önemli bir potansiyel taşıdığını göstermektedir.

Keywords

• Kanser
• Sitotoksik aktivite
• PC3 hücreleri
• Benzimidazol

Project Number

TSG-2024-9516

References

1. Noori-Daloii MR, Ebadi N. Pharmacogenomics and cancer stem cells. Medical sciences. 2015;25(1):1–15.
2. Hosseini M, Jahani Y, Mahmoudi M, Eshraghian MR, Yahyapour Y, Keshtkar AA. The assessment of risk factors for prostate cancer in Mazandaran province, Iran. Scientific journal of Gorgan university of medical sciences. 2008;10(3):58–64.
3. Kerru N, Gummidi L, Maddila S, Gangu KK, Jonnalagadda SB. A review on recent advances in nitrogen-containing molecules and their biological applications. Molecules. 2020;25 1909.
4. Harrison M, Holen K, Liu G. Beyond Taxanes: a Review of Novel Agents that Target Mitotic Tubulin and Microtubules, Kinases, and Kinesins. Clin Adv Hematol Oncol. 2009;7:54–64.
5. Nussbaumer S, Bonnabry P, Veuthey J, Fleury-Souverain S. Analysis of Anticancer Drugs:A Review. Talanta. 2011;85:2265–2289.
6. Bilici , Akkoç, S. In vitro cytotoxicity in A549, Hepg2, MCF-7, and DLD-1 cancer cell lines and ADME/toxin analysis of a benzimidazole derivative. journal of king saud university – science. 2025;37(2):1-6.
7. Subudhi SK. New approaches to immunotherapy for metastatic castration-resistant prostate cancer. Clin Adv Hematol Oncol. 2019;17 283–286.
8. Siegel, R.L., Miller, K.D., Jemal, A. Cancer statistics. CA Cancer J Clin. 2018;68:7–30.

9. Woolley DW. Some biological effects produced by benzimidazole and their reversal by purines. J. Biol. Chem. 1944;152 225–232.
10. Fang Y, Zhou H, Gu Q, Xu J. Synthesis and evaluation of tetrahydroisoquinoline-benzimidazole hybrids as multifunctional agents for the treatment of Alzheimer’s disease. Eur. J. Med. Chem. 2019;167 133–145.
11. Shimomura I, Yokoi A, Kohama I, Kumazaki M, Tada Y. Drug library screen reveals benzimidazole derivatives as selective cytotoxic agents for KRAS-mutant lung cancer. Cancer Lett. 2019;451 11–22.
12. Huynh TK, Nguyen TH, Nguyen TC, Hoang TK. Synthesis and insight into the structure-activity relationships of 2-phenylbenzimidazoles as prospective anticancer agents. RSC Adv. 2020;10(35):20543-20551.
13. Kim U, Shin C, Kim CY, Ryu B, Kim J, Bang J. Albendazole exerts antiproliferative effects on prostate cancer cells by inducing reactive oxygen species generation. Oncol Lett. 2021;21(5):395.
14. Djemoui A, Naouri A, Ouahrani MR, Djemoui D, Lahcene S, Lahrech MB. A step-by-step synthesis of triazole-benzimidazole-chalcone hybrids: Anticancer activity in human cells. J. Mol. Struct. 2020.
15. He Z, Qiao H, Yang F, Zhou W, Gong Y, Zhang X. Novel thiosemicarbazone derivatives containing indole fragment as potent and selective anticancer agent. Eur. J. Med. Chem. 2019;184 111764.
16. Afifi OS, Shaaban OG, Abd El Razik HA, Shams El-Dine SE-DA, Ashour FA, El-Tombary AA. Synthesis and biological evaluation of purine-pyrazole hybrids containing thiazole, thiazolidinone, or rhodanine moieties as 15-LOX inhibitors with anticancer and antioxidant potential. Bioorg. Chem. 2019;87 821–837.